Marcoumar

Phenprocoumon, the active ingredient in Marcoumar, is a vitamin K antagonist presented as an oral tablet for oral use. It is employed to prevent and treat venous thromboembolism, such as deep vein thrombosis and pulmonary embolism, and to lower the risk of stroke in patients with atrial fibrillation.

GNH USA supplies Marcoumar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Marcoumar, a vitamin K antagonist, is indicated for several thromboembolic conditions.

- Deep vein thrombosis: prevents clot extension and recurrence. - Pulmonary embolism: facilitates resolution of existing emboli and reduces mortality. - Atrial fibrillation (stroke prevention): lowers the risk of cardioembolic stroke. - Venous thromboembolism (overall): provides long‑term anticoagulation to prevent new clot formation.

Phenprocoumon may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Minor bleeding (e.g., gum or nosebleeds) - Bruising or hematoma formation - Gastrointestinal discomfort - Skin rash or itching - Elevated liver enzymes - Headache

Serious or Rare Side Effects: - Severe hemorrhage (intracranial or gastrointestinal) - Allergic anaphylaxis - Skin necrosis (rare) - Hepatic failure - Thrombocytopenia - Spontaneous bleeding into joints

When prescribing Phenprocoumon, clinicians should observe several safety measures to reduce the risk of complications.

- Dose individualization: adjust based on INR monitoring and patient response. - Bleeding risk assessment: evaluate history of hemorrhage, surgery, or trauma before initiation. - Pregnancy contraindication: avoid use in pregnant women due to fetal risk. - Concomitant disease monitoring: watch for liver disease, renal impairment, or uncontrolled hypertension. - Drug‑food interactions: maintain consistent vitamin K intake from diet. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Phenprocoumon interacts with several medicines that can alter its anticoagulant effect.

Major Interactions (Avoid): - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) – may cause dangerous over‑anticoagulation. - Antiplatelet agents (e.g., clopidogrel, aspirin) – increase bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – potentiate gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Antibiotics such as macrolides or quinolones – may modestly raise INR. - Herbal supplements containing St John’s wort – can reduce anticoagulant effect. - Vitamin K‑rich foods (green leafy vegetables) – may diminish efficacy.